News from cardiocell llc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 17, 2016, 09:15 ET Positive Results From Study Sponsored by CardioCell Post in the American Heart Association's Journal "Circulation Research"

Results from a study sponsored by CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, form ...


Aug 29, 2016, 10:31 ET European Society of Cardiology (ESC) Congress Presentation Reveals Results From Pre-Clinical Study Using CardioCell's Stem Cells for Acute Myocardial Infarction (AMI)

EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for...


Aug 28, 2016, 08:01 ET European Society of Cardiology (ESC) Congress Poster Session Reveals Results From Pre-Clinical Study Using CardioCell's Stem Cells for Chronic Ischemic Cardiomyopathy

EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 -- Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for...


Aug 28, 2016, 02:01 ET CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications

EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 -- Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for...


Aug 16, 2016, 09:15 ET Three CardioCell-Sponsored Studies Reveal Results at the European Society of Cardiology (ESC) Congress 2016

EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular...


Jun 14, 2016, 09:15 ET European Society of Cardiology (ESC) Selects CardioCell's Heart Failure (HF) Study Results for ESC Congress 2016 Late-Breaking Science Session

CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces that the European Society of ...


Apr 19, 2016, 09:15 ET CardioCell Completes Enrollment for a Phase IIa Clinical Trial Using Its Stem Cells for Participants With Chronic Heart Failure

CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, fulfills enrollment for its Phase IIa...


Mar 22, 2016, 09:15 ET CardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center

CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, welcomes MedStar...


Dec 01, 2015, 09:15 ET CardioCell Plans Phase IIb Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure

CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, intends to proceed with ...


Oct 21, 2015, 11:00 ET CardioCell Board Members and Clinical Trial Leads Collaborate on Peer-Reviewed Paper Published in the Journal of Cardiovascular Medicine

CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, announces that...


Mar 10, 2015, 10:00 ET CardioCell Adds Stony Brook University to Sites Conducting a Phase IIa Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure

CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that designs allogeneic stem-cell therapies for cardiovascular indications, expands...